{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:11:50Z","timestamp":1791612710848,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":881,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009664","name":"Spanish Society of Cardiology","doi-asserted-by":"publisher","award":["SEC\/MHE-MOV-INT 21\/001"],"award-info":[{"award-number":["SEC\/MHE-MOV-INT 21\/001"]}],"id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TRANSFORM HF"},{"name":"Heart and Stroke Foundation\/University of Toronto Polo Chair in Cardiology Young Investigator Award"},{"DOI":"10.13039\/100009664","name":"Sociedad Espa\u00f1ola de Cardiolog\u00eda","doi-asserted-by":"publisher","award":["SEC\/MHE\u2010MOV\u2010INT 21\/001"],"award-info":[{"award-number":["SEC\/MHE\u2010MOV\u2010INT 21\/001"]}],"id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Studies in cardiogenic shock (CS) often have a heterogeneous population of patients, including those with acute myocardial infarction and acute decompensated heart failure (ADHF-CS). The therapeutic profile of milrinone may benefit patients with ADHF-CS. We compared the outcomes and haemodynamic trends in ADHF-CS receiving either milrinone or dobutamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients presenting with ADHF-CS (from 2014 to 2020) treated with a single inodilator (milrinone or dobutamine) were included in this study. Clinical characteristics, outcomes, and haemodynamic parameters were collected. The primary endpoint was 30 day mortality, with censoring at the time of transplant or left ventricular assist device implantation. A total of 573 patients were included, of which 366 (63.9%) received milrinone and 207 (36.1%) received dobutamine. Patients receiving milrinone were younger, had better kidney function, and lower lactate at admission. In addition, patients receiving milrinone received mechanical ventilation or vasopressors less frequently, whereas a pulmonary artery catheter was more frequently used. Milrinone use was associated with a lower adjusted risk of 30 day mortality (hazard ratio = 0.52, 95% confidence interval 0.35\u20130.77). After propensity-matching, the use of milrinone remained associated with a lower mortality (hazard ratio = 0.51, 95% confidence interval 0.27\u20130.96). These findings were associated with improved pulmonary artery compliance, stroke volume, and right ventricular stroke work index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of milrinone compared with dobutamine in patients with ADHF-CS is associated with lower 30 day mortality and improved haemodynamics. These findings warrant further study in future randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14379","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:44:22Z","timestamp":1686876262000},"page":"2577-2587","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Improved Mortality and Haemodynamics with Milrinone in Cardiogenic Shock Due to Acute Decompensated Heart Failure"],"prefix":"10.1093","volume":"10","author":[{"given":"Eduard","family":"Rodenas-Alesina","sequence":"first","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Luis Scolari","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki N.","family":"Wang","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshan H.","family":"Brahmbhatt","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"National Heart & Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Mihajlovic","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Fung","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filio","family":"Billia","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Overgaard","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Southlake Regional Health Centre , Newmarket, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Luk","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, Division of Cardiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2026012114083243100_ehf214379-bib-0001","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"2026012114083243100_ehf214379-bib-0002","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012114083243100_ehf214379-bib-0003","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ahj.2007.04.033","article-title":"The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the acutely decompensated heart","volume":"154","author":"Costanzo","year":"2007","journal-title":"Am Heart J"},{"key":"2026012114083243100_ehf214379-bib-0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114083243100_ehf214379-bib-0005","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"2026012114083243100_ehf214379-bib-0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114083243100_ehf214379-bib-0007","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012114083243100_ehf214379-bib-0008","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/add6bc4f-dec0-4c95-a609-67563469b831","article-title":"The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis","volume":"8","author":"Pirracchio","year":"2013","journal-title":"PLoS ONE"},{"key":"2026012114083243100_ehf214379-bib-0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/CCM.0b013e3181ffe0eb","article-title":"Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study","volume":"39","author":"Levy","year":"2011","journal-title":"Crit Care Med"},{"key":"2026012114083243100_ehf214379-bib-0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","article-title":"Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction","volume":"72","author":"Levy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114083243100_ehf214379-bib-0011","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.25011\/cim.v42i2.32813","article-title":"Efficacy of milrinone and dobutamine in low cardiac output states: systematic review and meta-analysis","volume":"42","author":"Mathew","year":"2019","journal-title":"Clin Invest Med"},{"key":"2026012114083243100_ehf214379-bib-0012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114083243100_ehf214379-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007099","article-title":"Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock","volume":"13","author":"Thayer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026012114083243100_ehf214379-bib-0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic SHOCK. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012114083243100_ehf214379-bib-0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.696138","article-title":"Inotrope use and intensive care unit mortality in patients with cardiogenic shock: an analysis of a large electronic intensive care unit database","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012114083243100_ehf214379-bib-0016","article-title":"Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome","volume":"11","author":"Uhlig","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012114083243100_ehf214379-bib-0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021570","article-title":"Implications of myocardial infarction on management and outcome in cardiogenic shock","volume":"10","author":"Jung","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012114083243100_ehf214379-bib-0018","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cardfail.2021.08.010","article-title":"Heart failure-related cardiogenic shock: pathophysiology, evaluation and management considerations: review of heart failure-related cardiogenic shock","volume":"27","author":"Abraham","year":"2021","journal-title":"J Card Fail"},{"key":"2026012114083243100_ehf214379-bib-0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026012114083243100_ehf214379-bib-0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cardfail.2021.08.014","article-title":"De novo vs acute-on-chronic presentations of heart failure-related cardiogenic shock: insights from the Critical Care Cardiology Trials Network Registry","volume":"27","author":"Bhatt","year":"2021","journal-title":"J Card Fail"},{"key":"2026012114083243100_ehf214379-bib-0021","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.cardfail.2022.08.007","article-title":"Palliative inotropes in advanced heart failure: comparing outcomes between milrinone and dobutamine","volume":"28","author":"Sami","year":"2022","journal-title":"J Card Fail"},{"key":"2026012114083243100_ehf214379-bib-0022","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ehf2.13812","article-title":"Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis","volume":"9","author":"Szarpak","year":"2022","journal-title":"ESC Heart Failure"},{"key":"2026012114083243100_ehf214379-bib-0023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cardfail.2021.07.013","article-title":"Right ventricular dysfunction is common and identifies patients at risk of dying in cardiogenic shock","volume":"27","author":"Jain","year":"2021","journal-title":"J Card Fail"},{"key":"2026012114083243100_ehf214379-bib-0024","first-page":"33","article-title":"Cardiogenic shock due to predominantly right ventricular failure complicating acute myocardial infarction","volume":"10","author":"Josiassen","year":"2021","journal-title":"Eur Hear journal Acute Cardiovasc care"},{"key":"2026012114083243100_ehf214379-bib-0025","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019877161","article-title":"The prognostic value of pulmonary artery compliance in cardiogenic shock","volume":"9","author":"Zorzi","year":"2019","journal-title":"Pulm Circ"},{"key":"2026012114083243100_ehf214379-bib-0026","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.cardfail.2021.04.002","article-title":"Estimation of stressed blood volume in patients with cardiogenic shock from acute myocardial infarction and decompensated heart failure","volume":"27","author":"Whitehead","year":"2021","journal-title":"J Card Fail"},{"key":"2026012114083243100_ehf214379-bib-0027","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00003246-200003000-00023","article-title":"Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism","volume":"28","author":"Iribe","year":"2000","journal-title":"Crit Care Med"},{"key":"2026012114083243100_ehf214379-bib-0028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000542-199901000-00012","article-title":"Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB)","volume":"90","author":"M\u00f6llhoff","year":"1999","journal-title":"Anesthesiology"},{"key":"2026012114083243100_ehf214379-bib-0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/jcan.2001.21954","article-title":"Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass","volume":"15","author":"Yamaura","year":"2001","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026012114083243100_ehf214379-bib-0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcrc.2019.12.022","article-title":"Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery","volume":"57","author":"Lannemyr","year":"2020","journal-title":"J Crit Care"},{"key":"2026012114083243100_ehf214379-bib-0031","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00005344-198711000-00003","article-title":"Effects of milrinone on systemic hemodynamics and regional circulations in dogs with congestive heart failure: comparison with dobutamine","volume":"10","author":"Liang","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114083243100_ehf214379-bib-0032","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/sux001","article-title":"The inodilator levosimendan as a treatment for acute heart failure in various settings","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur Hear J Suppl J Eur Soc Cardiol"},{"key":"2026012114083243100_ehf214379-bib-0033","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012114083243100_ehf214379-bib-0034","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114083243100_ehf214379-bib-0035","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"Landoni","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114083243100_ehf214379-bib-0036","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2577\/64704728\/eschf_10_4_2577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2577\/64704728\/eschf_10_4_2577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:09:07Z","timestamp":1769022547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/4\/2577\/8285282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,6,15]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14379","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"2022-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}